| 000 | 02717 a2200901 4500 | ||
|---|---|---|---|
| 005 | 20250516121056.0 | ||
| 264 | 0 | _c20130116 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1038/clpt.2012.184 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDanese, E | |
| 245 | 0 | 0 |
_aImpact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cDec 2012 |
||
| 300 |
_a746-56 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; Systematic Review | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 | _aAlleles |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCoumarins _xadministration & dosage |
| 650 | 0 | 4 | _aCross-Sectional Studies |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xgenetics |
| 650 | 0 | 4 | _aCytochrome P450 Family 4 |
| 650 | 0 | 4 | _aEthnicity |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMixed Function Oxygenases _xgenetics |
| 650 | 0 | 4 |
_aPolymorphism, Genetic _xgenetics |
| 650 | 0 | 4 | _aPublication Bias |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 | _aVitamin K Epoxide Reductases |
| 700 | 1 | _aMontagnana, M | |
| 700 | 1 | _aJohnson, J A | |
| 700 | 1 | _aRettie, A E | |
| 700 | 1 | _aZambon, C F | |
| 700 | 1 | _aLubitz, S A | |
| 700 | 1 | _aSuarez-Kurtz, G | |
| 700 | 1 | _aCavallari, L H | |
| 700 | 1 | _aZhao, L | |
| 700 | 1 | _aHuang, M | |
| 700 | 1 | _aNakamura, Y | |
| 700 | 1 | _aMushiroda, T | |
| 700 | 1 | _aKringen, M K | |
| 700 | 1 | _aBorgiani, P | |
| 700 | 1 | _aCiccacci, C | |
| 700 | 1 | _aAu, N T | |
| 700 | 1 | _aLangaee, T | |
| 700 | 1 | _aSiguret, V | |
| 700 | 1 | _aLoriot, M A | |
| 700 | 1 | _aSagreiya, H | |
| 700 | 1 | _aAltman, R B | |
| 700 | 1 | _aShahin, M H A | |
| 700 | 1 | _aScott, S A | |
| 700 | 1 | _aKhalifa, S I | |
| 700 | 1 | _aChowbay, B | |
| 700 | 1 | _aSuriapranata, I M | |
| 700 | 1 | _aTeichert, M | |
| 700 | 1 | _aStricker, B H | |
| 700 | 1 | _aTaljaard, M | |
| 700 | 1 | _aBotton, M R | |
| 700 | 1 | _aZhang, J E | |
| 700 | 1 | _aPirmohamed, M | |
| 700 | 1 | _aZhang, X | |
| 700 | 1 | _aCarlquist, J F | |
| 700 | 1 | _aHorne, B D | |
| 700 | 1 | _aLee, M T M | |
| 700 | 1 | _aPengo, V | |
| 700 | 1 | _aGuidi, G C | |
| 700 | 1 | _aMinuz, P | |
| 700 | 1 | _aFava, C | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 92 _gno. 6 _gp. 746-56 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/clpt.2012.184 _zAvailable from publisher's website |
| 999 |
_c22245502 _d22245502 |
||